SecBot SecBot
8-K/A ·Filed Nov 19, 2026

CTSO

Cytosorbents Corp
NEUTRAL
Impact 4/10
Horizonmonths Processed2d 23h ago SEC0001104659-26-129936
8-K with no item list reported
Actionable Insight • Neutral

The company achieved operating cash flow breakeven, a key milestone, but revenue growth remains modest at 3% and Germany sales declined 21%. The next major catalyst is the DrugSorb-ATR De Novo submission to the FDA in early 2027. Monitor for updates on FDA interactions and German sales force rebuilding.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

CTSO drug pipeline →

CytoSorb

▼ Bearish Named in this 8-K/A
Impact
Phase
Approved / Commercialized
Time to market
Already on the market (CE-marked in Europe, FDA-cleared in US)
Next catalyst
None dated

What to watchWatch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$5.13
T+0 close · Nov 19, 2026 · via day close
Latest settled
−18.91%
T+1 · $4.16
Vs SPY
−15.27%
α at T+1
Next horizon
T+5
in 5d
  1. T+0 · Nov 19 $5.13entry
  2. T+1 · 2d ago −18.91%α −15.27% · $4.16
  3. T+5 · in 5d Pending
  4. T+20 · in 26d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CytoSorbents filed an 8-K/A amending its Q3 2026 earnings release to correct immaterial errors in foreign currency transaction losses, balance sheet amounts, and certain revenue percentages. The core financial results (revenue, gross profit, operating expenses, operating loss, and cash) are unchanged. The company reported Q3 2026 revenue of $9.7 million (+3% YoY), achieved operating cash flow breakeven of +$43,000 (excluding restructuring payments), and narrowed its adjusted EBITDA loss by 86% to $0.3 million. The company is advancing its DrugSorb-ATR De Novo submission to the FDA for early 2027.

Key Facts

  • Q3 2026 revenue $9.7 million, up 3% from $9.5 million in Q3 2025
  • Gross margin improved to 75% from 70% a year ago
  • Operating loss improved 59% to $1.2 million from $2.9 million in Q3 2025
  • Net loss was $2.1 million ($0.65 per share) vs $3.2 million ($1.01 per share) in Q3 2025
  • Generated positive operating cash flow of approximately $43,000, excluding $251,000 in restructuring payments
  • Total cash, cash equivalents, and restricted cash was $5.7 million at September 30, 2026
  • Adjusted EBITDA loss narrowed 86% to $0.3 million from $2.0 million in Q3 2025
  • Distributor and strategic partner sales grew 18% YoY; Germany sales declined 21% YoY
  • DrugSorb-ATR De Novo submission to FDA planned for early 2027
  • The amendment corrected non-cash foreign currency losses and related amounts; previously reported revenue, gross profit, operating expenses, and cash were unaffected

Financial Impact

Q3 2026 revenue $9.7M (+3% YoY), operating loss improved to $1.2M, net loss $2.1M, operating cash flow +$43K (excluding restructuring). Cash balance $5.7M.

revenuegross marginoperating lossnet lossoperating cash flowadjusted EBITDA

Risk Factors

  • Germany sales declined 21% YoY; rebuilding sales force may take time to show results
  • Cash balance of $5.7M is low relative to $17.5M in current debt maturities
  • Stockholders' equity is negative $2.3 million, indicating potential balance sheet stress
  • DrugSorb-ATR FDA approval is uncertain and not guaranteed

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K/A Filing (Primary)0001104659-26-129936
Document: tm2630146d1_ex99-2.htm0001104659-26-129936
Document: tm2630146d1_8k.htm0001104659-26-129936
Document: 0001104659-26-129936-index-headers.html0001104659-26-129936
Document: 0001104659-26-129936-index.html0001104659-26-129936
Document: 0001104659-26-129936.txt0001104659-26-129936

Track record

12 reports on CTSO

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 20, 20261d ago 424B5 Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
  2. Nov 20, 20261d ago 8-K Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
  3. Nov 19, 20263d ago 8-K/A Neutral 4/10 Viewing Entry $5.13 Now $4.16 −18.91% settles Feb 18
  4. Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
  5. Nov 12, 20269d ago Press Release Neutral 4/10 Entry $4.87 Now $4.16 −14.58% settles Feb 11
  6. Nov 12, 20269d ago 8-K Neutral 5/10 No price data
  7. Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
  8. Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
  9. Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
  10. Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Mon (26h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 19, 2026